An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer

European Journal of Cancer

Volumn 36, Issue SUPPL. 4, 2000, Pages 82-84

  Buzdar, A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Aromatase inhibitors; Breast; Treatment

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; FORMESTANE; LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0033744956     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(00)00238-0     Document Type: Article

References (13)

1. Endocrine aspects of the clinical management of breast cancer - Current issues
2. Anastrozole, a potent and selective aromatase inhibitor, versus megoestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
3. Anastrozole versus megastrol acetate in postmenopausal women with advanced breast cancer: Results of a survival update based on a combined analysis of data from two mature phase III trials
4. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
5. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma
6. First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer
7. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer
8. Vorozole versus 'Megace' in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen
9. 'Rivizor' versus aminoglutethimide (AG) in the second-line endocrine treatment of postmenopausal patients with advanced breast cancer (ABC) following tamoxifen failure
10. 'Arimidex' as neoadjuvant therapy causes large reductions in tumour volume in postmenopausal women with large operable breast cancers
11. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (Abc) in postmenopausal (Pm) women - Combined analysis from two identically designed multicenter trials
12. Preliminary results of a large comparitive multi-centre clinical trial comparing the efficacy and tolerability of Arimidex(TM) (Anastrozole) and tamoxifen (tamoxifen) in postmenopausal women with advanced breast cancer (ABC)
13. Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in postmenopausal breast cancer